Literature DB >> 25015826

NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.

Qiangjun Sui1, Jian Zhang2, Xiaoxia Sun1, Cai Zhang1, Qiuju Han1, Zhigang Tian3.   

Abstract

STAT3 is highly activated in a wide variety of cancers and functions to promote tumor survival. We previously reported that blocking STAT3 activation inhibited human hepatocellular carcinoma (HCC) growth in vitro, but whether this treatment also triggered antitumor immune responses in vivo remained unknown. In this study, we found that blocking the STAT3 pathway in HCC cells dramatically inhibited murine HCC growth in vivo and prolonged survival of tumor-bearing mice. Importantly, the presence of STAT3-blocked HCC augmented NK cell cytotoxicity against HCC and increased expression of molecules associated with NK cell activation and cytotoxicity. In T cell-deficient nude mice, a unique NK cell-mediated antitumor function against STAT3-blocked HCC was suggested. NK cells were shown to be necessary and sufficient in NK or T cell depletion experiments, or by adoptively transferring NK cells. Furthermore, regulatory T cells and immunosuppressive IL-10 and TGF-β cytokines were reduced in mice bearing STAT3-blocked HCC cells, suggesting that these factors may be involved in HCC-induced NK cell suppression. These findings indicate that blocking STAT3 in HCC cells can initiate innate immunity in vivo.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25015826     DOI: 10.4049/jimmunol.1302389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

2.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

3.  Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.

Authors:  Kun-Yu Teng; Jianfeng Han; Xiaoli Zhang; Shu-Hao Hsu; Shun He; Nissar A Wani; Juan M Barajas; Linda A Snyder; Wendy L Frankel; Michael A Caligiuri; Samson T Jacob; Jianhua Yu; Kalpana Ghoshal
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

Review 4.  Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.

Authors:  Min Yu; Zonghai Li
Journal:  Front Med       Date:  2017-08-05       Impact factor: 4.592

Review 5.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

6.  Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.

Authors:  Jiantao Han; Chao Ke; Bin Jiang; Hongjian Zhou; Hanbin Xu; Xingwang Xie
Journal:  Clin Exp Immunol       Date:  2021-10-10       Impact factor: 4.330

Review 7.  Myeloid derived suppressor cells and the release of micro-metastases from dormancy.

Authors:  Saraswoti Khadge; Kathryn Cole; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2021-05-20       Impact factor: 4.510

Review 8.  Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.

Authors:  Cheng Sun; Hao-yu Sun; Wei-hua Xiao; Cai Zhang; Zhi-gang Tian
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

Review 9.  Regulation of Natural Killer Cell Function by STAT3.

Authors:  Nicholas A Cacalano
Journal:  Front Immunol       Date:  2016-04-11       Impact factor: 7.561

Review 10.  Liver Cancer Immunity.

Authors:  Sumera Rizvi; Juan Wang; Anthony B El-Khoueiry
Journal:  Hepatology       Date:  2020-11-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.